Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AF Janus-associated kinase (JAK) inhibitors
L04AF04 Filgotinib
D11106 Filgotinib maleate (JAN/USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11106 Filgotinib maleate (JAN/USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG01991 Filgotinib
D11106 Filgotinib maleate
Metabolizing enzyme substrate
DG02970 CES substrate
DG03241 CES1 substrate
DG01991 Filgotinib
D11106 Filgotinib maleate
DG03192 CES2 substrate
DG01991 Filgotinib
D11106 Filgotinib maleate
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D11106 Filgotinib maleate
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D11106 Filgotinib maleate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11106 Filgotinib maleate (JAN/USAN) <JP>
JAK2
D11106 Filgotinib maleate (JAN/USAN) <JP>
JAK3
D11106 Filgotinib maleate (JAN/USAN) <JP>
TYK2
D11106 Filgotinib maleate (JAN/USAN) <JP>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11106
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11106
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11106
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11106
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG01991 Filgotinib
Metabolizing enzyme substrate
DG02970 CES substrate
DG03241 CES1 substrate
DG01991 Filgotinib
DG03192 CES2 substrate
DG01991 Filgotinib